secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2026-05-12T11:08:37+00:00
Accession:  0001628280-26-033870
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719
--------------------------------------------------------------------------------

- Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
- R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.
- Cash and equivalents $289.9M; expected to fund operations into 2028.
- Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.
- Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/0001628280-26-033870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/sion-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer